AlphaStocks
6.4
Consider Buy

Gilead Sciences, Inc. (GILD)

As of Sep 19, 2026, Gilead Sciences, Inc. (GILD) scores 6.4/10 on AlphaStocks' five-model composite, #31 of 168 Health Care stocks. At $150, GILD trades 21% below its model fair value of $190.

Health Care / Biotechnology

S&P 500

$149.99

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 19, 2026

#31out of 168 in Health Care

Is GILEAD SCIENCES, INC. a Good Investment in 2026?

GILEAD SCIENCES, INC. (GILD) scores 6.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates GILEAD SCIENCES, INC. as Strong (7/9). However, the Graham model rates it Caution — Significantly above fair value. GILEAD SCIENCES, INC. currently trades 21% below its estimated fair value of $190. GILEAD SCIENCES, INC. ranks #31 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E22.1ROE38.5Market Cap188BDiv Yield2.5

Estimated Fair Value

$190.0121% below

Trading below estimated fair value. EPS grew 1673% year-over-year. ROE of 38% signals strong profitability. P/E of 22x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

Growth rate vs price (PEG)

Greenblatt

Attractive

Earnings yield 5.6% · ROC 83%

Frequently Asked Questions

Is GILEAD SCIENCES, INC. (GILD) a good investment?
As of Sep 19, 2026, Gilead Sciences, Inc. (GILD) scores 6.4/10 on AlphaStocks' five-model composite, #31 of 168 Health Care stocks. At $150, GILD trades 21% below its model fair value of $190. That is a middle-of-the-pack score with no strong signal either way.
What is GILEAD SCIENCES, INC.'s Piotroski F-Score?
GILEAD SCIENCES, INC.'s Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is GILD overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $190, GILD appears undervalued. The stock currently trades 21% below its estimated fair value. Trading below estimated fair value. EPS grew 1673% year-over-year. ROE of 38% signals strong profitability. P/E of 22x is moderate for this quality level.
How does GILD compare to other Health Care stocks?
GILEAD SCIENCES, INC. ranks #31 out of 168 stocks in the Health Care sector, placing it in the top 18% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about GILD?
AlphaStocks evaluates GILD using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 6.4/10.

Similar Stocks

ABBVINCYHRMY

Compare GILD with

ABBV vs GILDGILD vs INCYGILD vs HRMYGILD vs PARRGILD vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer